The Purdue Pharma settlement of 2024 marks a significant turning point in the ongoing battle against opioid manufacturers. Over 40 states have joined forces to hold the company accountable for its role in the opioid crisis.
These states are seeking to recover billions of dollars in damages and costs associated with the opioid epidemic. The lawsuit alleges that Purdue Pharma, the maker of OxyContin, engaged in deceptive marketing practices and failed to warn consumers about the risks of addiction.
The settlement is a result of years of litigation and negotiations between the states and Purdue Pharma. It's a major victory for those who have lost loved ones to the opioid crisis or are still struggling with addiction.
Recommended read: Leveraged Pharma Etf
Purdue Pharma Settlement
The $7.4 billion settlement with Purdue Pharma is a historic agreement that resolves litigation against the Sacklers over the opioid crisis.
A prior settlement had been struck down by the Supreme Court, but this new deal has been reached with all 50 states, Washington D.C., and four U.S. territories signing on.
The Sacklers will walk away from this deal with a lot of their fortune intact, despite denying any wrongdoing and claiming they led the company ethically.
The settlement will support opioid addiction treatment, prevention, and recovery programs over the next 15 years, with a significant amount of funds distributed in the first three years.
The Sacklers will pay $1.5 billion in the first payment, followed by $500 million after one year, an additional $500 million after two years, and $400 million after three years.
This deal will end the Sacklers' ownership of Purdue and bar them from making, selling, or marketing opioids in the U.S.
Check this out: When Will the Bcbs Settlement Be Paid
U.S. States Involved
All 50 states, Washington, D.C., and four U.S. territories have agreed to sign a $7.4 billion settlement with Purdue Pharma.
The attorneys general in 55 states and territories have signed on to the historic settlement.
The Sacklers' ownership of Purdue will end as a result of the settlement, and they will be barred from making, selling, or marketing opioids in the U.S.
The settlement will support opioid addiction treatment, prevention, and recovery programs over the next 15 years.
A significant amount of the funds will be distributed in the first three years, with the Sacklers paying $1.5 billion and Purdue paying approximately $900 million in the first payment.
Explore further: Purdue Pharma Family
States' Reactions
Massachusetts Attorney General Maura Healey stated that the settlement was "a step in the right direction" but noted that it doesn't hold the company's executives accountable.
The state of Oklahoma has already filed a lawsuit against the company, seeking to hold the Sackler family accountable for their role in the opioid crisis.
New York and Connecticut have also filed their own lawsuits against Purdue Pharma, seeking to recover costs associated with the opioid epidemic.
The settlement would require Purdue Pharma to pay out $4.5 billion over nine years to address the opioid crisis.
The company's assets would be sold off to pay for the settlement, with the Sackler family's assets being used to pay a significant portion of the costs.
The settlement would also establish a new company to take over Purdue Pharma's assets, with the goal of producing non-addictive painkillers.
The new company would be led by a board of independent directors and would be required to prioritize the development of non-addictive painkillers.
Recommended read: Wörwag Pharma
$7.4 Billion Settlement Amount
The $7.4 billion settlement amount is a significant figure, but it's worth noting that it will be paid out over a period of 15 years. This means that the Sacklers will have to pay a total of $1.5 billion in the first three years, with the amount decreasing over time.
The settlement is a result of years of litigation against Purdue Pharma, the company behind the opioid OxyContin. A prior settlement had been struck down by the Supreme Court, but this new agreement has been reached with all 50 states, Washington, D.C., and four U.S. territories signing on.
The $7.4 billion will be used to support opioid addiction treatment, prevention, and recovery programs over the next 15 years. A significant amount of the funds will be distributed in the first three years, with the Sacklers paying $1.5 billion and Purdue paying approximately $900 million in the first payment.
This settlement is a step towards justice for those affected by the opioid crisis, but it's clear that many people feel it's insufficient. Connecticut Attorney General William Tong said, "There will never be enough justice, accountability or money to restore the families whose lives have been wrecked or to right the terrible consequences of the Sackler family's craven misconduct."
Purdue Pharma and Sacklers
A historic $7.4 billion settlement has been reached with Purdue Pharma, the maker of OxyContin, the drug widely seen as a key driver of the opioid epidemic.
The Sacklers, the family behind Purdue Pharma, could still face a lot of litigation from individuals who say they were harmed.
The settlement is a hit to their collective pocketbooks, but they will be allowed to pay out the funds over a decade-and-a-half.
The Sacklers deny wrongdoing, saying they led the company ethically even though it pleaded guilty repeatedly to criminal activity on their watch.
They will walk away from this with a lot more legal protection and a lot of their fortune intact.
Featured Images: pexels.com
